BioCryst price target raised to $28 from $25 at Citizens

Citizens analyst Jonathan Wolleben raised the firm’s price target on BioCryst (BCRX) to $28 from $25 and keeps an Outperform rating on the shares. Orladeyo posted a typical seasonal Q1 dip with sales slightly below expectations but steady patient starts and reaffirmed 2026 guidance, while confidence remains high in longer-term growth driven by continued patient additions, pricing, international expansion through the Neopharmed deal, and pipeline opportunities including navenibart and BCX17725 that could support meaningful upside through the next decade, the analyst tells investors in a research note.